Global rEgistry on decongestioN Therapy Using Less invasivE UltraFiltration

Terminated

Conditions: Acute Heart Failure
Cardiac Decompensation
Volume Overload

Interventions: Device: periph. minimal invasive ultrafiltration

Registration Number: NCT02769351

Lead Sponsor: Fresenius Medical Care Deutschland GmbH

Brief Summary: In patients with advanced volume overload, minimally invasive ultrafiltration treatment in the acute phase can have a positive effect on clinical outcome. The aim is to collect treatment data in the context of a prospective registry of the safety and performance of minimally invasive ultrafiltration. The data will be recorded via an electronic case report form (eCRF); the eCRF runs on a server located in Germany and complies with current data protection regulations. It is intended to include about 300-500 patients with advanced volume overload at a minimum of 10 sites. In addition, data on a disease management programme (in-body measurement and home monitoring) will be recorded in up to 40 of these patients. The treatment data from each patient will be recorded over 12 months. An interim analysis will be performed after 150 patients have been observed for 6 months. The knowledge about ultrafiltration in volume overload obtained from the registry, in some cases in combination with a disease management programme, is intended to improve the body of evidence. In addition, the data will be used for hypothesis generation.

Detailed Description: There may be various reasons why an increased accumulation of fluid occurs in tissue. The most common causes include heart failure, kidney failure or cirrhosis of the liver. In rare cases, oedema can develop following septicaemia. The usual treatment of oedema involves diuretics, i.e. water tablets, which remove excess fluid from the body and which can be administered either orally or intravenously. For some years now, it has also been possible to use ultrafiltration to treat oedema. This involves filtering and removing excess fluid from the blood. This individual method enables a precisely defined amount of fluid to be withdrawn. Access to the blood circulation is usually via a central venous catheter, as in acute dialysis. Current international treatment guidelines recommend that consideration should be given to ultrafiltration therapy in the context of treatment of diuretic-resistant volume overload (e.g. second- or third-line therapy for acute decompensated heart failure). There are, however, to date no clinical data on a combined treatment regimen of diuretics and supportive ultrafiltration. Accordingly, ultrafiltration may be included in clinical guidelines either only with a low level of evidence (e.g. IIb in the ACCF/AHA guidelines) or not at all (ESC guidelines). The main reasons for the limited body of evidence for ultrafiltration are, on the one hand, the invasive nature of the usual procedures (these usually require the insertion of a central venous catheter) and structural barriers in the health system (ultrafiltration is normally offered by nephrologists and not by cardiologists). With an increasing clinical need and limited medical alternatives, particularly in view of the frequently occurring diuretic resistance in heart failure, there is an urgent medical need to fill this gap in evaluation evidence. In the context of the registry, the CHIARA system, a minimally invasive (i.e. via a peripheral venous access) extracorporeal ultrafiltration system, is used for the treatment of decompensated volume overload. The CHIARA system has a CE mark for the intended purpose of ultrafiltration of the blood of patients suffering from heart failure, acute or chronic renal failure or excess body fluid. It is planned to use the medical device in connection with this intended purpose only. In participating hospitals, patients will be treated with this new treatment strategy of minimally invasive ultrafiltration treatment in support of diuretic drug therapy in the acute phase of volume overload. It is possible with the use of ultrafiltration therapy to control volume overload and reduce it on an individual basis, so that diuretics can be given sparingly and, as a consequence, diuretic resistance and a deterioration of renal function due to diuretic uptitration can be avoided.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 104

Inclusion Criteria

≥18 years
Inpatient-treated patients with acute volume overload, preferably in association with cardiac decompensation with signs of incipient diuretic resistance (lack of increase in urine output despite significant escalation of diuretic therapy; e.g. ≥80 mg furosemide / 24 h or less than 1375 mL urine output/40 mg furosemide per 24 h or equivalent dose of other loop diuretics [established clinically or from the medical history])
New York Association Functional Class (NYHA) III-IV at inclusion
Systolic or diastolic cardiac dysfunction (HF-REF or HF-PEF)
Adequate venous access (preferably peripheral arm vein) allowing a flow rate ≥ 60 mL / min
Written consent to the use of data in the registry (where necessary, by a legal guardian).

Exclusion Criteria

Contraindication to anticoagulation (e.g. known heparin-induced thrombocytopenia, severe bleeding)
Terminal renal failure (stage V, GFR <15 mL)
Cardiogenic shock, e.g. in association with acute coronary syndrome (ACS)
Other diseases or factors that, in the study doctor's opinion, constitute a potential contraindication to ultrafiltration
Pregnant women, women in labour, breast-feeding women or women of childbearing potential, who are without adequate contraception or are planning a family. NB: a pregnancy test is performed systematically in women of childbearing age and the patient is not included in the event of pregnancy (positive test). It is absolutely essential that women, who have a negative test and who are included in the study, have an effective contraception.

Study & Design

Study Type: OBSERVATIONAL

Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
periph. minimal invasive ultrafiltration	periph. minimal invasive ultrafiltration	Patients with volume overload receiving ultrafiltration

Primary Outcome Measures

Name	Time	Method
Rehospitalisation (Yes/no) Due to Exacerbation of Heart Failure/Volume Overload of Other Origin	12 months	The number of rehospitalizations due to heart failure resp. volume overload has been measured as a clinical endpoint and analyzed based on the AP.

Secondary Outcome Measures

Name	Time	Method
Significant Deterioration of Kidney Function - eGFR (Estimated Glomerular Filtration Rate)	Recruitment, Discharge from index hospitalization, Outapteint visit I (3-6 months), Outpatient visit II (12 months)	Significant deterioration of kidney function has been measured as a safety endpoint and analyzed based on the SP. The variables have been measured at recruitment, discharge from the index hospitalization, Outpatient visit I (3-9 months) and Outpatient visit II (12 months).
Significant Deterioration of Kidney Function - Urea	Recruitment; Discharge from Index Hospitalization; Outpatient visit I (3-6 months); Outpatient visit II (12 months)	Significant deterioration of kidney function has been measured as a safety endpoint and analyzed based on the SP. The variables have been measured at recruitment, discharge from the index hospitalization, Outpatient visit I (3-9 months) and Outpatient visit II (12 months).
Significant Deterioration of Kidney Function - Creatinine	Recruitment; Discharge from Index Hospitalization; Outpatient visit I (3-9 months); Outpatient visit II ( 12 months)	Significant deterioration of kidney function has been measured as a safety endpoint and analyzed based on the SP. The variables have been measured at recruitment, discharge from the index hospitalization, Outpatient visit I (3-9 months) and Outpatient visit II (12 months).
Significant Deterioration of Kidney Function - Cystatin	recruitment, discharge from the index hospitalization, Outpatient visit I (3-9 months), Outpatient visit II (12 months)	Significant deterioration of kidney function has been measured as a safety endpoint and analyzed based on the SP. The variables have been measured at recruitment, discharge from the index hospitalization, Outpatient visit I (3-9 months) and Outpatient visit II (12 months).

Trial Locations

Locations (19): Universitätsklinikum Mannheim
🇩🇪
Mannheim, Baden-Württemberg, Germany
Falun Hospital
🇸🇪
Falun, Sweden
Uniklinik RWTH Aachen
🇩🇪
Aachen, North Rhine-Westphalia, Germany
University Hospital Örebro
🇸🇪
Örebro, Sweden
Städtisches Klinikum Braunschweig
🇩🇪
Braunschweig, Niedersachsen, Germany
HELIOS Klinikum Erfurt
🇩🇪
Erfurt, Thueringen, Germany
Uppsala University Hospital
🇸🇪
Uppsala, Sweden
Helios Klinikum Duisburg
🇩🇪
Duisburg, North Rhine-Westphalia, Germany
Danderyd University Hospital
🇸🇪
Stockholm, Sweden
UniversitätsSpital Zurich
🇨🇭
Zurich, Switzerland
Helios Klinik Attendorn
🇩🇪
Attendorn, Nordrhein-Westfalen, Germany
Helios Klinikum Berlin Buch
🇩🇪
Berlin, Germany
Karolinska University Hospital
🇸🇪
Stockholm, Sweden
Klinikum Stuttgart
🇩🇪
Stuttgart, Baden Württemberg, Germany
Helios Klinik für Herzchirurgie GmbH Karlsruhe
🇩🇪
Karlsruhe, Baden- Württemberg, Germany
Universitätsklinikum Heidelberg
🇩🇪
Heidelberg, Baden Württemberg, Germany
Helios Klinikum Hildesheim
🇩🇪
Hildesheim, Niedersachsen, Germany
SUS Skanes University Hosptal
🇸🇪
Malmö, Sweden
Kantonsspital Aarau
🇨🇭
Aarau, Switzerland